Drug Profile
Research programme: psychiatric disorder therapeutics - Boehringer Ingelheim/Circuit Therapeutics
Latest Information Update: 28 Jan 2018
Price :
$50
*
At a glance
- Originator Boehringer Ingelheim; Circuit Therapeutics
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Psychiatric disorders
Most Recent Events
- 28 Jan 2018 No recent reports of development identified for research development in Psychiatric-disorders in Germany
- 28 Jan 2018 No recent reports of development identified for research development in Psychiatric-disorders in USA
- 18 Dec 2013 Early research in Psychiatric disorders in USA and Germany (unspecified route)